The Pan American Health Organization reiterated that the benefits of the AstraZeneca vaccine far outweigh the risk of thrombosis.
Mexico City (apro)-The Pan American Health Organization (PAHO) reiterated that the benefits of the AstraZeneca vaccine far outweigh the risk of thrombosis.
After the European Medicines Agency (EMA) confirmed the link between the vaccine and the drug and believed that the sequel should be regarded as an “extremely unlikely side effect,” Sylvan Aldiji, the head of the covid-19 accident Sylvain Aldighieri suggested continuing to use the organisms developed by AstraZeneca Pharmaceuticals and Oxford University.
He said that based on the information currently available, the World Health Organization and the European Medicines Agency believe that the benefits of the AstraZeneca vaccine against the implied death risk of covid-19 continue to outweigh the risks, and recommend continued vaccination.
He added that the EMA evaluation showed that 62 rare cases of cerebral venous sinus diffuse intravascular coagulation or thrombosis were recorded. He emphasized that in Europe, there are 62 cases out of more than 30 million doses.
Therefore, the Pan American Health Organization recommends strict monitoring of all vaccines, encourage vaccination, and report all reported adverse reactions.
The Latin American organization recalled that the delivery of the AstraZeneca vaccine is still continuing, although the announcement of the suspension of shipments of doses made by the Indian Serum Institute through the COVAX mechanism may affect Bolivia, Nicaragua and Haiti.
Jarbas Barbosa, deputy director of the Pan American Health Organization, commented: “I think it is important that these contracts must be fully fulfilled so that we can ship vaccines to these countries. According to the agreement.
Costa Rica has received 43,200 doses of vaccine from the 218,400 doses it will receive in the first round today, while the Dominican Republic and Uruguay have also received the vaccine last week.
The Pan American Health Organization announced that COVAX will begin to dispense limited doses. Janssen will continue to produce Pfizer vaccines in June, June and July.
Regarding Venezuela, Ciro Ugarte, director of health emergencies, recalled that the country had not yet paid the first payment for the mechanism, and only then would it be possible to provide a usable vaccine.